Basiliximab approved for use in renal transplant patients.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D017277:Drug Approval; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000628:therapy*; D016030:Kidney Transplantation; D011993:Recombinant Fusion Proteins; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab